Page last updated: 2024-12-04

edoxudin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID1814
SCHEMBL ID65580
MeSH IDM0079426
PubMed CID66377
CHEMBL ID318153
CHEBI ID135051
SCHEMBL ID65579
MeSH IDM0079426

Synonyms (91)

Synonym
1-(2-deoxypentofuranosyl)-5-ethylpyrimidine-2,4(1h,3h)-dione
TIMTEC1_004024
smr001223874
5-ethyl-2'-deoxyuridine ; edoxudine
MLS001360450
HMS1545G20
eudr
5-ethyl-1-[4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,3-dihydropyrimidine-2,4-d ione
HMS3056J10
HMS3369L22
SCHEMBL65580
AKOS024282522
.beta.-5-ethyl-2'-deoxyuridine
edurid (salt/mix)
.beta.-5-ethyldeoxyuridine
XACKNLSZYYIACO-UHFFFAOYSA-N
5-ethyl-1-(2'-deoxy-.beta.-d-ribofuranosyl)uracil
FT-0772436
5-ethyl-2-deoxyuridine
A920347
DTXSID70860153
MLS001076558
MLS000069564 ,
edoxudine
15176-29-1
etudr
5-ethyl-durd
5-ethyl-2'-deoxyuridine
5-ethyl-1-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]pyrimidine-2,4-dione
edoxudine (usan/inn)
D03956
5-ethyldeoxyuridine
brn 0755089
beta-5-ethyl-2'-deoxyuridine
edoxudina [spanish]
epoxudine
rwj 15817
aedurid
edoxudin
einecs 239-226-1
2'-deoxy-5-ethyluridine
edoxudine [usan:inn]
orf 15817
edoxudinum [latin]
beta-5-ethyldeoxyuridine
ccris 2349
5-ethyl-1-(2'-deoxy-beta-d-ribofuranosyl)uracil
uridine, 2'-deoxy-5-ethyl-
smr000058816
CHEBI:135051
cid_66377
5-ethyl-1-((2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yl)pyrimidine-2,4(1h,3h)-dione
cid_1814
bdbm50132292
5-ethyl-2''-deoxyuridine
5-ethyl-1-((2r,5r)-4-hydroxy-5-hydroxymethyl-tetrahydro-furan-2-yl)-1h-pyrimidine-2,4-dione
nsc-758405
CHEMBL318153 ,
5-ethyl-3-(2'-deoxyribosyl)uracil
rwj-15817
orf-15817
15zqm81y3r ,
nsc 758405
edoxudinum
edoxudina
unii-15zqm81y3r
dtxcid2025890
dtxsid4045890 ,
cas-15176-29-1
tox21_111390
HMS2234L05
BRD-K86892782-001-13-9
SCHEMBL65579
XACKNLSZYYIACO-DJLDLDEBSA-N
edoxudine [mart.]
edoxudine [who-dd]
edoxudine [usan]
edoxudine [inn]
edoxudine [mi]
CS-4524
HY-B1011
OPERA_ID_1297
AKOS027320600
5-ethyl-2 inverted exclamation mark -deoxyuridine
DB13421
5-ethyl-1-((2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)pyrimidine-2,4(1h,3h)-dione
Q987691
F85211
MS-23610
5-ethyl-1-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,2,3,4-tetrahydropyrimidine-2,4-dione
EN300-18385593

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
"The pharmacokinetic behaviour of the virostatic drug 5-ethyl-2'-deoxyuridine (EtUdR, Aedurid) and its metabolite 5-ethyluracil was determined after intravenous and oral application in a nonindividual study using inbred rats."( [Pharmacokinetics of 5-ethyl-2'-desoxyuridine in the rat].
Hempel, B; Kaul, R, 1985
)
0.27
" EDU was eliminated from blood with a half-life of 35."( Pharmacokinetics and bioavailability of 5-ethyl-2'-deoxyuridine and its novel (5R,6R)-5-bromo-6-ethoxy-5,6-dihydro prodrugs in mice.
Cheraghali, AM; Knaus, EE; Kumar, R; Wiebe, LI, 1995
)
0.29

Bioavailability

ExcerptReferenceRelevance
" EDU showed a 49% bioavailability in mice after a 100 mg/kg po dose."( Bioavailability and pharmacokinetic parameters for 5-ethyl-2'-deoxyuridine.
Cheraghali, AM; Knaus, EE; Wiebe, LI, 1994
)
0.29
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

ExcerptRelevanceReference
" At each dosage level, semilogarithmic plots of concentration vs."( Elimination of the antiviral drug 5-ethyl-2'-deoxyuridine by the isolated perfused rat liver.
Joly, JM; Williams, WM,
)
0.13
"Pharmacokinetic parameters for 5-ethyl-2'-deoxyuridine (EDU) were determined following intravenous (iv) and oral (po) dosing in male Balb-C mice and iv dosing in male Sprague-Dawley rats."( Bioavailability and pharmacokinetic parameters for 5-ethyl-2'-deoxyuridine.
Cheraghali, AM; Knaus, EE; Wiebe, LI, 1994
)
0.29
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
pyrimidine 2'-deoxyribonucleoside
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (18)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
ATAD5 protein, partialHomo sapiens (human)Potency0.89130.004110.890331.5287AID504467
TDP1 proteinHomo sapiens (human)Potency16.36010.000811.382244.6684AID686979
urokinase-type plasminogen activator precursorMus musculus (house mouse)Potency10.00000.15855.287912.5893AID540303
plasminogen precursorMus musculus (house mouse)Potency10.00000.15855.287912.5893AID540303
urokinase plasminogen activator surface receptor precursorMus musculus (house mouse)Potency10.00000.15855.287912.5893AID540303
Guanine nucleotide-binding protein GHomo sapiens (human)Potency50.11871.995325.532750.1187AID624287
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASEHomo sapiens (human)Potency5.62340.003245.467312,589.2998AID2517
TDP1 proteinHomo sapiens (human)Potency12.73410.000811.382244.6684AID686978; AID686979
estrogen nuclear receptor alphaHomo sapiens (human)Potency23.71010.000229.305416,493.5996AID743079
67.9K proteinVaccinia virusPotency6.63760.00018.4406100.0000AID720579; AID720580
chromobox protein homolog 1Homo sapiens (human)Potency112.20200.006026.168889.1251AID540317
DNA polymerase iota isoform a (long)Homo sapiens (human)Potency0.63100.050127.073689.1251AID588590
urokinase-type plasminogen activator precursorMus musculus (house mouse)Potency2.51190.15855.287912.5893AID540303
plasminogen precursorMus musculus (house mouse)Potency2.51190.15855.287912.5893AID540303
urokinase plasminogen activator surface receptor precursorMus musculus (house mouse)Potency2.51190.15855.287912.5893AID540303
lamin isoform A-delta10Homo sapiens (human)Potency0.44670.891312.067628.1838AID1487
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
exodeoxyribonuclease V subunit RecBEscherichia coli str. K-12 substr. MG1655IC50 (µMol)118.69600.10000.10000.1000AID492957
exodeoxyribonuclease V subunit RecCEscherichia coli str. K-12 substr. MG1655IC50 (µMol)118.69600.10000.10000.1000AID492957
Thymidine kinase Macacine alphaherpesvirus 1IC50 (µMol)0.15000.15002.57504.2000AID326127
exodeoxyribonuclease V subunit RecBEscherichia coli str. K-12 substr. MG1655IC50 (µMol)97.14250.10000.10000.1000AID492957; AID652151
exodeoxyribonuclease V subunit RecCEscherichia coli str. K-12 substr. MG1655IC50 (µMol)97.14250.10000.10000.1000AID492957; AID652151
Thymidylate kinaseMycobacterium tuberculosis H37RvKi1,140.00004.50008.500010.0000AID210904
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Thymidine phosphorylaseHomo sapiens (human)Km719.00000.16000.16000.1600AID211066
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (16)

Processvia Protein(s)Taxonomy
negative regulation of inflammatory response to antigenic stimulusGuanine nucleotide-binding protein GHomo sapiens (human)
renal water homeostasisGuanine nucleotide-binding protein GHomo sapiens (human)
G protein-coupled receptor signaling pathwayGuanine nucleotide-binding protein GHomo sapiens (human)
regulation of insulin secretionGuanine nucleotide-binding protein GHomo sapiens (human)
cellular response to glucagon stimulusGuanine nucleotide-binding protein GHomo sapiens (human)
mitochondrial genome maintenanceThymidine phosphorylaseHomo sapiens (human)
angiogenesisThymidine phosphorylaseHomo sapiens (human)
pyrimidine nucleobase metabolic processThymidine phosphorylaseHomo sapiens (human)
pyrimidine nucleoside metabolic processThymidine phosphorylaseHomo sapiens (human)
chemotaxisThymidine phosphorylaseHomo sapiens (human)
signal transductionThymidine phosphorylaseHomo sapiens (human)
cell differentiationThymidine phosphorylaseHomo sapiens (human)
regulation of myelinationThymidine phosphorylaseHomo sapiens (human)
dTMP catabolic processThymidine phosphorylaseHomo sapiens (human)
regulation of transmission of nerve impulseThymidine phosphorylaseHomo sapiens (human)
regulation of gastric motilityThymidine phosphorylaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (7)

Processvia Protein(s)Taxonomy
G protein activityGuanine nucleotide-binding protein GHomo sapiens (human)
adenylate cyclase activator activityGuanine nucleotide-binding protein GHomo sapiens (human)
1,4-alpha-oligoglucan phosphorylase activityThymidine phosphorylaseHomo sapiens (human)
protein bindingThymidine phosphorylaseHomo sapiens (human)
growth factor activityThymidine phosphorylaseHomo sapiens (human)
thymidine phosphorylase activityThymidine phosphorylaseHomo sapiens (human)
protein homodimerization activityThymidine phosphorylaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (2)

Processvia Protein(s)Taxonomy
plasma membraneGuanine nucleotide-binding protein GHomo sapiens (human)
cytosolThymidine phosphorylaseHomo sapiens (human)
cytosolThymidine phosphorylaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (110)

Assay IDTitleYearJournalArticle
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID216540Antiviral activity against vesicular stomatitis virus1986Journal of medicinal chemistry, Apr, Volume: 29, Issue:4
Synthesis and antitumor and antiviral properties of 5-alkyl-2'-deoxyuridines, 3',5'-cyclic monophosphates, and neutral cyclic triesters.
AID341996Antimicrobial activity against Streptococcus sp. 07941-1 after 20 hrs2007Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8
Deoxyribonucleoside kinases activate nucleoside antibiotics in severely pathogenic bacteria.
AID341997Antimicrobial activity against Streptococcus sp. 07706-1 after 20 hrs2007Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8
Deoxyribonucleoside kinases activate nucleoside antibiotics in severely pathogenic bacteria.
AID83720In Vitro antiviral activity against HSV-1 at 0.05 ug/mL concentration1994Journal of medicinal chemistry, Sep-16, Volume: 37, Issue:19
Synthesis of new acyclic pyrimidine nucleoside analogs as potential antiviral drugs.
AID85893Inhibition of plaque formation in monolayers of HSV-1 E-377 Vero cells by 50%2001Journal of medicinal chemistry, Oct-11, Volume: 44, Issue:21
Synthesis and antiviral activity of novel 5-(1-cyanamido-2-haloethyl) and 5-(1-hydroxy(or methoxy)-2-azidoethyl) analogues of uracil nucleosides.
AID217916Compound was tested for the inhibition of the replication of herpes simplex virus (HSV-I strain 377) in vero cells in exp. No. 21986Journal of medicinal chemistry, Jan, Volume: 29, Issue:1
Synthesis and antiviral activity of the carbocyclic analogues of 5-ethyl-2'-deoxyuridine and of 5-ethynyl-2'-deoxyuridine.
AID211066Michaelis-Menten constant (Km) against horse liver thymidine phosphorylase1980Journal of medicinal chemistry, Aug, Volume: 23, Issue:8
Thymidine phosphorylase. Substrate specificity for 5-substituted 2'-deoxyuridines.
AID217910Compound was tested for the inhibition of the replication of herpes simplex virus (HSV-2 strain MS) in vero cells in exp. No. 21986Journal of medicinal chemistry, Jan, Volume: 29, Issue:1
Synthesis and antiviral activity of the carbocyclic analogues of 5-ethyl-2'-deoxyuridine and of 5-ethynyl-2'-deoxyuridine.
AID210904Inhibitory activity against thymidine monophosphate kinase (TMPK) in Mycobacterium tuberculosis2003Bioorganic & medicinal chemistry letters, Sep-15, Volume: 13, Issue:18
Thymidine and thymidine-5'-O-monophosphate analogues as inhibitors of Mycobacterium tuberculosis thymidylate kinase.
AID85715Antiviral activity against Herpes Simplex Virus-1(F)1986Journal of medicinal chemistry, Apr, Volume: 29, Issue:4
Synthesis and antitumor and antiviral properties of 5-alkyl-2'-deoxyuridines, 3',5'-cyclic monophosphates, and neutral cyclic triesters.
AID81372Minimum concentration not causing a microscopically detectable cytotoxic alteration of normal human embryonic lung fibroblast (HELF) morphology1988Journal of medicinal chemistry, Feb, Volume: 31, Issue:2
Synthesis and biological activities of 4-O-(difluoromethyl)-5-substituted-uracil nucleoside analogues.
AID165779Cytostatic activity against proliferation of Raji/0 cells1986Journal of medicinal chemistry, Apr, Volume: 29, Issue:4
Synthesis and antitumor and antiviral properties of 5-alkyl-2'-deoxyuridines, 3',5'-cyclic monophosphates, and neutral cyclic triesters.
AID84605Concentration required to reduce the number of viral plaques in vivo cell monolayers of herpes simplex virus type 2.1989Journal of medicinal chemistry, Feb, Volume: 32, Issue:2
Synthesis and antiviral activity of phosphonoacetic and phosphonoformic acid esters of 5-bromo-2'-deoxyuridine and related pyrimidine nucleosides and acyclonucleosides.
AID84950Ability to reduce plaque formation of herpes simplex virus type 2 (HSV-2) by 50% in human embryonic lung fibroblast (HELF) cell cultures1988Journal of medicinal chemistry, Feb, Volume: 31, Issue:2
Synthesis and biological activities of 4-O-(difluoromethyl)-5-substituted-uracil nucleoside analogues.
AID86022Inhibition of plaque formation in monolayers of HSV-1 KOS Vero cells by 50%2001Journal of medicinal chemistry, Oct-11, Volume: 44, Issue:21
Synthesis and antiviral activity of novel 5-(1-cyanamido-2-haloethyl) and 5-(1-hydroxy(or methoxy)-2-azidoethyl) analogues of uracil nucleosides.
AID218133Antiviral activity against vaccinia virus1986Journal of medicinal chemistry, Apr, Volume: 29, Issue:4
Synthesis and antitumor and antiviral properties of 5-alkyl-2'-deoxyuridines, 3',5'-cyclic monophosphates, and neutral cyclic triesters.
AID91301Inhibitory concentration of the drug against the cytopathic effect for ellen strain of varicella zoster virus-2 (VZV-2) in human HFF cells1993Journal of medicinal chemistry, Aug-20, Volume: 36, Issue:17
Synthesis and antiviral activity of novel 5-(1-azido-2-haloethyl) and 5-(1-azido-, amino-, or methoxyethyl) analogs of 2'-deoxyuridine.
AID84935Inhibition of viral cytopathic effect in infected human foreskin fibroblast cell monolayers of HSV-2 MS Vero cells by 50%2001Journal of medicinal chemistry, Oct-11, Volume: 44, Issue:21
Synthesis and antiviral activity of novel 5-(1-cyanamido-2-haloethyl) and 5-(1-hydroxy(or methoxy)-2-azidoethyl) analogues of uracil nucleosides.
AID84766Antiviral activity against Herpes Simplex Virus-2(Lyons)1986Journal of medicinal chemistry, Apr, Volume: 29, Issue:4
Synthesis and antitumor and antiviral properties of 5-alkyl-2'-deoxyuridines, 3',5'-cyclic monophosphates, and neutral cyclic triesters.
AID342001Antimicrobial activity against Streptococcus pyogenes AP1 after 20 hrs2007Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8
Deoxyribonucleoside kinases activate nucleoside antibiotics in severely pathogenic bacteria.
AID165904Inhibitory concentration of the drug against the antigen production against P3HR-1 strain of epstein barr virus-2 (EBV) in Raji cells1993Journal of medicinal chemistry, Aug-20, Volume: 36, Issue:17
Synthesis and antiviral activity of novel 5-(1-azido-2-haloethyl) and 5-(1-azido-, amino-, or methoxyethyl) analogs of 2'-deoxyuridine.
AID280941Cytotoxicity against mouse L1210/0 cells after 48 hrs2007Journal of medicinal chemistry, Apr-05, Volume: 50, Issue:7
Probing the anticancer activity of nucleoside analogues: a QSAR model approach using an internally consistent training set.
AID341995Antimicrobial activity against Escherichia coli ATCC 25922 after 20 hrs2007Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8
Deoxyribonucleoside kinases activate nucleoside antibiotics in severely pathogenic bacteria.
AID83721In Vitro antiviral activity against HSV-1 at 0.5 ug/mL concentration1994Journal of medicinal chemistry, Sep-16, Volume: 37, Issue:19
Synthesis of new acyclic pyrimidine nucleoside analogs as potential antiviral drugs.
AID83725In Vitro cytotoxicity against HSV-1 at 5 ug/mL concentration1994Journal of medicinal chemistry, Sep-16, Volume: 37, Issue:19
Synthesis of new acyclic pyrimidine nucleoside analogs as potential antiviral drugs.
AID977602Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID232840Ratio of Vmax to that of dThd (Vmax = 0.14)1980Journal of medicinal chemistry, Aug, Volume: 23, Issue:8
Thymidine phosphorylase. Substrate specificity for 5-substituted 2'-deoxyuridines.
AID91299Inhibitory concentration of the drug against the cytopathic effect for MS strain of herpes simplex virus-2 (HSV-2) in human HFF cells1993Journal of medicinal chemistry, Aug-20, Volume: 36, Issue:17
Synthesis and antiviral activity of novel 5-(1-azido-2-haloethyl) and 5-(1-azido-, amino-, or methoxyethyl) analogs of 2'-deoxyuridine.
AID217508Inhibition of viral cytopathic effect in infected human foreskin fibroblast cell in monolayers of VZV Ellen Vero cells by 50%2001Journal of medicinal chemistry, Oct-11, Volume: 44, Issue:21
Synthesis and antiviral activity of novel 5-(1-cyanamido-2-haloethyl) and 5-(1-hydroxy(or methoxy)-2-azidoethyl) analogues of uracil nucleosides.
AID527283Antiviral activity against HBV infected in human 2.2.15 cell at 10 ug/ml2010Bioorganic & medicinal chemistry letters, Nov-15, Volume: 20, Issue:22
Antiviral activity of 2,3'-anhydro and related pyrimidine nucleosides against hepatitis B virus.
AID83722In Vitro antiviral activity against HSV-1 at 5 ug/mL concentration1994Journal of medicinal chemistry, Sep-16, Volume: 37, Issue:19
Synthesis of new acyclic pyrimidine nucleoside analogs as potential antiviral drugs.
AID83723In Vitro antiviral activity against HSV-1 at 50 ug/mL concentration1994Journal of medicinal chemistry, Sep-16, Volume: 37, Issue:19
Synthesis of new acyclic pyrimidine nucleoside analogs as potential antiviral drugs.
AID326138Cytotoxicity against african green monkey Vero cells after 2 days2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Sensitivity of monkey B virus (Cercopithecine herpesvirus 1) to antiviral drugs: role of thymidine kinase in antiviral activities of substrate analogs and acyclonucleosides.
AID341998Antimicrobial activity against Streptococcus sp. 07686-2 after 20 hrs2007Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8
Deoxyribonucleoside kinases activate nucleoside antibiotics in severely pathogenic bacteria.
AID83727In Vitro cytotoxicity against HSV-1 at 500 ug/mL concentration1994Journal of medicinal chemistry, Sep-16, Volume: 37, Issue:19
Synthesis of new acyclic pyrimidine nucleoside analogs as potential antiviral drugs.
AID84934Inhibition of viral cytopathic effect in infected human foreskin fibroblast cell in monolayers of HSV-2 ADVero cells by 50%2001Journal of medicinal chemistry, Oct-11, Volume: 44, Issue:21
Synthesis and antiviral activity of novel 5-(1-cyanamido-2-haloethyl) and 5-(1-hydroxy(or methoxy)-2-azidoethyl) analogues of uracil nucleosides.
AID342000Antimicrobial activity against Staphylococcus aureus CCM 885 after 20 hrs2007Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8
Deoxyribonucleoside kinases activate nucleoside antibiotics in severely pathogenic bacteria.
AID91297Inhibitory concentration of the drug against the cytopathic effect for E-377 strain of herpes simplex virus-1 (HSV-1) in human HFF cells1993Journal of medicinal chemistry, Aug-20, Volume: 36, Issue:17
Synthesis and antiviral activity of novel 5-(1-azido-2-haloethyl) and 5-(1-azido-, amino-, or methoxyethyl) analogs of 2'-deoxyuridine.
AID527285Cytotoxicity against human HuH7 cells2010Bioorganic & medicinal chemistry letters, Nov-15, Volume: 20, Issue:22
Antiviral activity of 2,3'-anhydro and related pyrimidine nucleosides against hepatitis B virus.
AID79633Ability to reduce the viral DNA in HBV infected primary duck hepatocytes to 50%2001Journal of medicinal chemistry, Oct-11, Volume: 44, Issue:21
Synthesis and antiviral activity of novel 5-(1-cyanamido-2-haloethyl) and 5-(1-hydroxy(or methoxy)-2-azidoethyl) analogues of uracil nucleosides.
AID326137Antiviral activity against Herpes simplex virus 1 F infected in african green monkey Vero cells assessed as plaque reduction after 36 to 48 hrs2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Sensitivity of monkey B virus (Cercopithecine herpesvirus 1) to antiviral drugs: role of thymidine kinase in antiviral activities of substrate analogs and acyclonucleosides.
AID91295Inhibitory concentration of the drug against the cytopathic effect for AD169 strain of epstein barr virus-2 (HCMV) in human HFF cells1993Journal of medicinal chemistry, Aug-20, Volume: 36, Issue:17
Synthesis and antiviral activity of novel 5-(1-azido-2-haloethyl) and 5-(1-azido-, amino-, or methoxyethyl) analogs of 2'-deoxyuridine.
AID218076Compound was evaluated for antiviral activity against Herpes Simplex Virus (HSV-1 strain 377) in vero cells in exp. No. 21986Journal of medicinal chemistry, Jan, Volume: 29, Issue:1
Synthesis and antiviral activity of the carbocyclic analogues of 5-ethyl-2'-deoxyuridine and of 5-ethynyl-2'-deoxyuridine.
AID326134Antiviral activity against Herpes B virus 24105 infected in african green monkey Vero cells assessed as plaque reduction after 36 to 48 hrs2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Sensitivity of monkey B virus (Cercopithecine herpesvirus 1) to antiviral drugs: role of thymidine kinase in antiviral activities of substrate analogs and acyclonucleosides.
AID326135Antiviral activity against Herpes B virus 32425 infected in african green monkey Vero cells assessed as plaque reduction after 36 to 48 hrs2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Sensitivity of monkey B virus (Cercopithecine herpesvirus 1) to antiviral drugs: role of thymidine kinase in antiviral activities of substrate analogs and acyclonucleosides.
AID326131Activity of Herpes B virus recombinant thymidine kinase at 100 uM2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Sensitivity of monkey B virus (Cercopithecine herpesvirus 1) to antiviral drugs: role of thymidine kinase in antiviral activities of substrate analogs and acyclonucleosides.
AID83726In Vitro cytotoxicity against HSV-1 at 50 ug/mL concentration1994Journal of medicinal chemistry, Sep-16, Volume: 37, Issue:19
Synthesis of new acyclic pyrimidine nucleoside analogs as potential antiviral drugs.
AID91307Concentration of the drug required to reduce the uptake of neural red stain by uninfected cell monolayers (HFF)1993Journal of medicinal chemistry, Aug-20, Volume: 36, Issue:17
Synthesis and antiviral activity of novel 5-(1-azido-2-haloethyl) and 5-(1-azido-, amino-, or methoxyethyl) analogs of 2'-deoxyuridine.
AID83716Ability to reduce plaque formation of herpes simplex virus type 1 (HSV-1) by 50% in human embryonic lung fibroblast (HELF) cell cultures1988Journal of medicinal chemistry, Feb, Volume: 31, Issue:2
Synthesis and biological activities of 4-O-(difluoromethyl)-5-substituted-uracil nucleoside analogues.
AID527284Antiviral activity against HBV infected in human 2.2.15 cell2010Bioorganic & medicinal chemistry letters, Nov-15, Volume: 20, Issue:22
Antiviral activity of 2,3'-anhydro and related pyrimidine nucleosides against hepatitis B virus.
AID326127Inhibition of Herpes B virus recombinant thymidine kinase-mediated [3H]TdR phosphorylation2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Sensitivity of monkey B virus (Cercopithecine herpesvirus 1) to antiviral drugs: role of thymidine kinase in antiviral activities of substrate analogs and acyclonucleosides.
AID165781Cytostatic activity against proliferation of Raji/TK cells1986Journal of medicinal chemistry, Apr, Volume: 29, Issue:4
Synthesis and antitumor and antiviral properties of 5-alkyl-2'-deoxyuridines, 3',5'-cyclic monophosphates, and neutral cyclic triesters.
AID91306Concentration of the drug required to reduce the proliferation of human foreskin fibroblast cells1993Journal of medicinal chemistry, Aug-20, Volume: 36, Issue:17
Synthesis and antiviral activity of novel 5-(1-azido-2-haloethyl) and 5-(1-azido-, amino-, or methoxyethyl) analogs of 2'-deoxyuridine.
AID977599Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID84765Antiviral activity against Herpes Simplex Virus-2(G)1986Journal of medicinal chemistry, Apr, Volume: 29, Issue:4
Synthesis and antitumor and antiviral properties of 5-alkyl-2'-deoxyuridines, 3',5'-cyclic monophosphates, and neutral cyclic triesters.
AID96640Cytostatic activity against proliferation of L1210/BdU cells1986Journal of medicinal chemistry, Apr, Volume: 29, Issue:4
Synthesis and antitumor and antiviral properties of 5-alkyl-2'-deoxyuridines, 3',5'-cyclic monophosphates, and neutral cyclic triesters.
AID326136Antiviral activity against Herpes B virus E90-136 infected in african green monkey Vero cells assessed as plaque reduction after 36 to 48 hrs2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Sensitivity of monkey B virus (Cercopithecine herpesvirus 1) to antiviral drugs: role of thymidine kinase in antiviral activities of substrate analogs and acyclonucleosides.
AID218081Compound was evaluated for antiviral activity against Herpes Simplex Virus (HSV-2 strain MS) in vero cells in exp. No. 21986Journal of medicinal chemistry, Jan, Volume: 29, Issue:1
Synthesis and antiviral activity of the carbocyclic analogues of 5-ethyl-2'-deoxyuridine and of 5-ethynyl-2'-deoxyuridine.
AID218228Compound was tested for the inhibition of the replication of herpes simplex virus (HSV-2 strain MS) in vero cells in exp. No. 21986Journal of medicinal chemistry, Jan, Volume: 29, Issue:1
Synthesis and antiviral activity of the carbocyclic analogues of 5-ethyl-2'-deoxyuridine and of 5-ethynyl-2'-deoxyuridine.
AID96638Cytostatic activity against proliferation of L1210/0 cells1986Journal of medicinal chemistry, Apr, Volume: 29, Issue:4
Synthesis and antitumor and antiviral properties of 5-alkyl-2'-deoxyuridines, 3',5'-cyclic monophosphates, and neutral cyclic triesters.
AID84763Antiviral activity against Herpes Simplex Virus-2(196)1986Journal of medicinal chemistry, Apr, Volume: 29, Issue:4
Synthesis and antitumor and antiviral properties of 5-alkyl-2'-deoxyuridines, 3',5'-cyclic monophosphates, and neutral cyclic triesters.
AID83724In Vitro antiviral activity against HSV-1 at 500 ug/mL concentration1994Journal of medicinal chemistry, Sep-16, Volume: 37, Issue:19
Synthesis of new acyclic pyrimidine nucleoside analogs as potential antiviral drugs.
AID86023Inhibition of plaque formation in monolayers of HSV-1 KOSSB(TK-) Vero cells by 50%2001Journal of medicinal chemistry, Oct-11, Volume: 44, Issue:21
Synthesis and antiviral activity of novel 5-(1-cyanamido-2-haloethyl) and 5-(1-hydroxy(or methoxy)-2-azidoethyl) analogues of uracil nucleosides.
AID85559Concentration required to reduce the number of viral plaques in vivo cell monolayers of herpes simplex virus type 1.1989Journal of medicinal chemistry, Feb, Volume: 32, Issue:2
Synthesis and antiviral activity of phosphonoacetic and phosphonoformic acid esters of 5-bromo-2'-deoxyuridine and related pyrimidine nucleosides and acyclonucleosides.
AID85716Antiviral activity against Herpes Simplex Virus-1(KOS)1986Journal of medicinal chemistry, Apr, Volume: 29, Issue:4
Synthesis and antitumor and antiviral properties of 5-alkyl-2'-deoxyuridines, 3',5'-cyclic monophosphates, and neutral cyclic triesters.
AID85717Antiviral activity against Herpes Simplex Virus-1 (McIntyre)1986Journal of medicinal chemistry, Apr, Volume: 29, Issue:4
Synthesis and antitumor and antiviral properties of 5-alkyl-2'-deoxyuridines, 3',5'-cyclic monophosphates, and neutral cyclic triesters.
AID341999Antimicrobial activity against Staphylococcus aureus ATCC 29213 after 20 hrs2007Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8
Deoxyribonucleoside kinases activate nucleoside antibiotics in severely pathogenic bacteria.
AID527281Antiviral activity against HBV infected in duck primary hepatocytes at 10 ug/ml2010Bioorganic & medicinal chemistry letters, Nov-15, Volume: 20, Issue:22
Antiviral activity of 2,3'-anhydro and related pyrimidine nucleosides against hepatitis B virus.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
AID1224864HCS microscopy assay (F508del-CFTR)2016PloS one, , Volume: 11, Issue:10
Increasing the Endoplasmic Reticulum Pool of the F508del Allele of the Cystic Fibrosis Transmembrane Conductance Regulator Leads to Greater Folding Correction by Small Molecule Therapeutics.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (72)

TimeframeStudies, This Drug (%)All Drugs %
pre-199034 (47.22)18.7374
1990's14 (19.44)18.2507
2000's7 (9.72)29.6817
2010's13 (18.06)24.3611
2020's4 (5.56)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 17.38

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index17.38 (24.57)
Research Supply Index2.08 (2.92)
Research Growth Index4.28 (4.65)
Search Engine Demand Index10.37 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (17.38)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Trials1 (1.39%)5.53%
Reviews0 (0.00%)6.00%
Reviews3 (4.17%)6.00%
Case Studies0 (0.00%)4.05%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Observational0 (0.00%)0.25%
Other7 (100.00%)84.16%
Other68 (94.44%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]